E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Male and female adult participants (= 18 years) with Ph+ CML or Ph+ ALL at the end of parent study, who are currently participating in an asciminib Novartis sponsored parent study |
|
E.1.1.1 | Medical condition in easily understood language |
cancer of the blood cells: CML and Ph+ ALL |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10009012 |
E.1.2 | Term | Chronic myelogenous leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10034877 |
E.1.2 | Term | Philadelphia chromosome positive |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to assess long term safety data and provide continued access to study treatment received in the parent protocol. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of this study is to evaluate clinical benefit as assessed by the Investigator. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed informed consent must be obtained prior to participation in the study. 2. Participant with Ph+ CML or Ph+ ALL, currently enrolled in a Novartis sponsored study, that has completed treatment phase and has fulfilled the requirements for the primary objective, receiving: -asciminib -asciminib in combination with imatinib or nilotinib or dasatinib -imatinib -nilotinib -bosutinib and, in the opinion of the Investigator, would benefit from continued treatment. 3. Participant has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements and is willing and able to comply with scheduled visits, treatment plans and any other study procedures. 4. Other protocol-defined inclusion criteria may apply
|
|
E.4 | Principal exclusion criteria |
1. Participant has been discontinued from parent study treatment due to any reason. 2. Participant currently has unresolved toxicities of grade 3 or 4 reported as possibly related to study treatment in the parent study, which have: - not resolved to Grade 2 or lower within 42 days and /or require dose interruption for longer than 42 days for hematological toxicities, - not resolved to Grade 2 or lower within 28 days and /or require dose interruption for longer than 28 days in case of non-hematological toxicities. 3. Participant’s ongoing treatment is currently approved and reimbursed at country level. 4. Pregnant or nursing (lactating) women. 5b. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 3 days after stopping asciminib. If local regulations or locally approved prescribing information are more stringent than the protocol required duration of contraception (Section 8.4.3), local regulations or locally approved prescribing information apply and will be described in the ICF. Participants receiving imatinib, nilotinib, bosutinib or dasatinib should be willing to follow the relevant contraception requirements as in the local prescribing information. 6a. Sexually active males receiving imatinib, nilotinib, bosutinib or dasatinib should be willing to follow the relevant contraception requirements as in the local prescribing information. 7. Applicable only for participants on bosutinib treatment at the end of the ABL001A2301 study that switch to asciminib treatment at enrollment: -Any Grade 3 or 4 toxicity which has not resolved to Grade 2 or lower within 28 days before starting asciminib treatment. -Asymptomatic (grade 2) pancreatitis if not resolved within 28 days. -QTcF > 480 msec or inability to determine QTc interval 8. Other protocol-defined exclusion criteria may apply |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The frequency and severity of AEs/SAEs |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Proportion of participants with clinical benefit as assessed by the investigator at scheduled visits |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Roll-over study, Bosutinib patients have the option to switch to asciminib during the study |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 8 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 80 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Singapore |
Taiwan |
Brazil |
Canada |
China |
Japan |
Korea, Republic of |
Lebanon |
Mexico |
Russian Federation |
Saudi Arabia |
United Kingdom |
United States |
Austria |
Bulgaria |
Czechia |
Denmark |
France |
Germany |
Italy |
Netherlands |
Poland |
Portugal |
Romania |
Spain |
Türkiye |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Study is expected to remain open for 5 years or until one of the below scenario occurs for all participants, whichever comes first: •ongoing treatment becomes available following product launch and/or subsequent reimbursement (where applicable) •benefit-risk profile of ongoing treatment for participant is no longer positive •participant meets treatment discontinuation criteria •other access program becomes available or is identified (i.e. compassionate use, MAP, etc.) for ongoing treatment
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |